Home About EMBARC What is EMBARC? Steering Committee International Advisory Board Registry Pharmacy Transparency Notice EMBARC Members Acknowledgements NEWS Latest News Newsletters 2019 Newsletters 2018 Newsletters 2017 Newsletters 2016 Newsletters 2015 RESEARCH Active projects FRIENDS Publications Research Roadmap EDUCATION Assessment and causes Courses and Resources EMBARC Webinar series – ‘Lessons in Bronchiectasis’ Microbiology NTM-lung References Severity assessment Treatment What is Bronchiectasis? Patient Resource Registry Documents EMBARC Registry EMBARC Registry
Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis. Choo JM, Abell GCJ, Thomson R, Morgan L, Waterer G, Gordon DL, Taylor SL, Leong LEX, Wesselingh SL, Burr LD, Rogers GB. Link to publication page: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907653 Journal Ref: mSphere. 2018 Apr 18;3(2). pii: e00103-18. doi: 10.1128/mSphere.00103-18. Print 2018 Apr 25.
